Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 12 | 1,020 | 48% |
| 2020 | 10 | 960 | 50% |
| 2021 | 7 | 865 | 52% |
| 2022 | 8 | 899 | 53% |
| 2023 | 9 | 889 | 55% |
| 2024 | 8 | 940 | 56% |
| 2025 from claims | – | 959 775–1,126 | 56% |
| 2026 forecast | – | 976 765–1,226 | 56% |
| 2027 forecast | – | 988 733–1,306 | 56% |
| 2028 forecast | – | 1,000 708–1,380 | 56% |
| 2029 forecast | – | 1,012 688–1,452 | 57% |
| 2030 forecast | – | 1,025 671–1,521 | 57% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in California; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 3 | 264+12%/yr | +12%/yr | 0.4 | 0% | 460 in 2030+9.6%/yr |
| Utah | 1 | 173+29%/yr | +29%/yr | 0.8 | 79% | 280 in 2030+8.3%/yr |
| Washington | 0 | 149−4.5%/yr | −4.5%/yr | 0.2 | 0% | 40 in 2030−20%/yr |
| Colorado | 0 | 122−2.6%/yr | −2.6%/yr | 0.3 | 0% | 150 in 2030+3.4%/yr |
| Oregon | 0 | 120+0.7%/yr | +0.7%/yr | 0.3 | 0% | 140 in 2030+2.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 337 | 21,034+1.6%/yr | +1.6%/yr | 6.71.1× | 42% | 26,600 in 2030+4%/yr |
| Tumor & fibroid embolization | 34 | 1,753+3.4%/yr | +3.4%/yr | 0.50.9× | 40% | 4,240 in 2030+16%/yr |
Tumor ablation in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
Exact Sciences leads with 33% of company spending on these surgeons in 2025, +9 pts on 2024.
In 2025, 19 companies reported engagement with California’s surgeons worth $1.1M in consulting, speaking, meals and travel tied to these products, about $132K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.